Cosmo Pharmaceuticals N.V. (COPN.SW)
CHF 47.45
(-0.52%)
CHF 47.45
(-0.52%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 19.69 Million EUR | -49.44% |
| 2022 | 47.48 Million EUR | 17.34% |
| 2021 | 40.48 Million EUR | 400.35% |
| 2020 | 7.83 Million EUR | 185.09% |
| 2019 | -7.02 Million EUR | 11.54% |
| 2018 | -12.32 Million EUR | 60.72% |
| 2017 | -28.81 Million EUR | -183.02% |
| 2016 | 28.43 Million EUR | 400.93% |
| 2015 | 262.96 Million EUR | -81.57% |
| 2014 | 35.7 Million EUR | 57.63% |
| 2013 | 22.65 Million EUR | -23.33% |
| 2012 | 29.6 Million EUR | 142.99% |
| 2011 | 11.39 Million EUR | 63.84% |
| 2010 | 7.42 Million EUR | -0.05% |
| 2009 | 7.42 Million EUR | -47.53% |
| 2008 | 14.15 Million EUR | 742.0% |
| 2007 | 2.08 Million EUR | 1815.31% |
| 2006 | -98 Thousand EUR | -103.9% |
| 2005 | 2.98 Million EUR | 1143.07% |
| 2004 | 202 Thousand EUR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | 47.12 Million EUR | 0.0% |
| 2024 Q1 | 47.12 Million EUR | 1563.65% |
| 2023 Q1 | 7.01 Million EUR | -46.55% |
| 2023 Q2 | 7.01 Million EUR | 0.0% |
| 2023 Q3 | 2.83 Million EUR | -59.63% |
| 2023 Q4 | 2.83 Million EUR | 0.0% |
| 2023 FY | - EUR | -49.44% |
| 2022 Q1 | 7.45 Million EUR | 3.74% |
| 2022 FY | - EUR | 17.34% |
| 2022 Q4 | 13.12 Million EUR | 0.0% |
| 2022 Q3 | 13.12 Million EUR | 76.08% |
| 2022 Q2 | 7.45 Million EUR | 0.0% |
| 2021 Q4 | 7.18 Million EUR | 0.0% |
| 2021 Q3 | 7.18 Million EUR | 318.36% |
| 2021 Q1 | 1.71 Million EUR | -40.61% |
| 2021 FY | - EUR | 400.35% |
| 2021 Q2 | 1.71 Million EUR | 0.0% |
| 2020 Q1 | 135.5 Thousand EUR | -95.52% |
| 2020 FY | - EUR | 185.09% |
| 2020 Q3 | 2.89 Million EUR | 2034.69% |
| 2020 Q4 | 2.89 Million EUR | 0.0% |
| 2020 Q2 | 135.5 Thousand EUR | 0.0% |
| 2019 Q3 | 3.02 Million EUR | 141.48% |
| 2019 Q2 | -7.29 Million EUR | 0.0% |
| 2019 Q1 | -7.29 Million EUR | -106.0% |
| 2019 Q4 | 3.02 Million EUR | 0.0% |
| 2019 FY | - EUR | 11.54% |
| 2018 Q3 | -3.54 Million EUR | -37.61% |
| 2018 Q1 | -2.57 Million EUR | -57.72% |
| 2018 FY | - EUR | 60.72% |
| 2018 Q2 | -2.57 Million EUR | 0.0% |
| 2018 Q4 | -3.54 Million EUR | 0.0% |
| 2017 Q3 | -1.63 Million EUR | -14.65% |
| 2017 Q4 | -1.63 Million EUR | 0.0% |
| 2017 FY | - EUR | -183.02% |
| 2017 Q1 | -1.42 Million EUR | -119.43% |
| 2017 Q2 | -1.42 Million EUR | 0.0% |
| 2016 FY | - EUR | 400.93% |
| 2016 Q4 | 7.32 Million EUR | 0.0% |
| 2016 Q3 | 7.32 Million EUR | 6.29% |
| 2016 Q2 | 6.89 Million EUR | 0.0% |
| 2016 Q1 | 6.89 Million EUR | -29.34% |
| 2015 Q2 | -9.67 Million EUR | 0.0% |
| 2015 FY | - EUR | -81.57% |
| 2015 Q4 | 9.75 Million EUR | -4.43% |
| 2015 Q1 | -9.67 Million EUR | -310.56% |
| 2015 Q3 | 10.2 Million EUR | 205.5% |
| 2014 Q2 | 9.5 Million EUR | 0.0% |
| 2014 Q4 | 4.59 Million EUR | -9.3% |
| 2014 Q1 | 9.5 Million EUR | 176.87% |
| 2014 Q3 | 5.06 Million EUR | -46.71% |
| 2014 FY | - EUR | 57.63% |
| 2013 FY | - EUR | -23.33% |
| 2013 Q4 | 3.43 Million EUR | 0.0% |
| 2013 Q1 | 4.67 Million EUR | 242.74% |
| 2013 Q2 | 4.67 Million EUR | 0.0% |
| 2013 Q3 | 3.43 Million EUR | -26.57% |
| 2012 Q4 | 1.36 Million EUR | 0.0% |
| 2012 Q3 | 1.36 Million EUR | -81.82% |
| 2012 FY | - EUR | 142.99% |
| 2012 Q1 | 7.5 Million EUR | 0.0% |
| 2012 Q2 | 7.5 Million EUR | 0.0% |
| 2011 Q3 | 3.04 Million EUR | 0.0% |
| 2011 Q1 | 3.04 Million EUR | 0.0% |
| 2011 Q2 | 3.04 Million EUR | 0.0% |
| 2011 FY | - EUR | 63.84% |
| 2011 Q4 | 7.5 Million EUR | 146.78% |
| 2010 FY | - EUR | -0.05% |
| 2010 Q3 | 1.85 Million EUR | 0.0% |
| 2010 Q2 | 1.85 Million EUR | 0.0% |
| 2010 Q1 | 1.85 Million EUR | 0.0% |
| 2010 Q4 | 3.04 Million EUR | 63.84% |
| 2009 Q1 | 1.85 Million EUR | 0.0% |
| 2009 FY | - EUR | -47.53% |
| 2009 Q4 | 1.85 Million EUR | -0.05% |
| 2009 Q3 | 1.85 Million EUR | 0.0% |
| 2009 Q2 | 1.85 Million EUR | 0.0% |
| 2008 FY | - EUR | 742.0% |
| 2008 Q4 | 1.85 Million EUR | -47.53% |
| 2008 Q2 | 3.53 Million EUR | 0.0% |
| 2008 Q1 | 3.53 Million EUR | 0.0% |
| 2008 Q3 | 3.53 Million EUR | 0.0% |
| 2007 FY | - EUR | 1815.31% |
| 2007 Q4 | 3.53 Million EUR | 777.5% |
| 2007 Q3 | 403.25 Thousand EUR | 0.0% |
| 2007 Q2 | 403.25 Thousand EUR | 0.0% |
| 2007 Q1 | 403.25 Thousand EUR | 0.0% |
| 2006 Q1 | 787.75 Thousand EUR | 0.0% |
| 2006 Q4 | 403.25 Thousand EUR | -48.81% |
| 2006 FY | - EUR | -103.9% |
| 2006 Q2 | 787.75 Thousand EUR | 0.0% |
| 2006 Q3 | 787.75 Thousand EUR | 0.0% |
| 2005 Q2 | 745.75 Thousand EUR | 0.0% |
| 2005 Q3 | 745.75 Thousand EUR | 0.0% |
| 2005 Q1 | 745.75 Thousand EUR | 0.0% |
| 2005 Q4 | 787.75 Thousand EUR | 5.63% |
| 2005 FY | - EUR | 1143.07% |
| 2004 Q4 | 745.75 Thousand EUR | 1376.73% |
| 2004 FY | - EUR | 0.0% |
| 2004 Q1 | 50.5 Thousand EUR | 0.0% |
| 2004 Q2 | 50.5 Thousand EUR | 0.0% |
| 2004 Q3 | 50.5 Thousand EUR | 0.0% |
| 2003 Q4 | 50.5 Thousand EUR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Roche Holding AG | 18.41 Billion CHF | 99.893% |
| Roche Holding AG | 18.41 Billion CHF | 99.893% |